Abner Antonio Murray/X
Jun 2, 2025, 08:33
Abner Antonio Murray: New data from the phase 3 HERTHENA-Lung02 trial at ASCO 2025
Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared on X:
“New data from the phase 3 HERTHENA-Lung02 trial at ASCO 2025: Patritumab deruxtecan (HER3-DXd) shows PFS benefit over platinum-based chemo in EGFR-mutant NSCLC post–3rd generation EGFR TKI.
PFS: HER3-DXd reduced risk of progression/death vs PBC (HR 0.77, p=0.011)
Intracranial activity: ORR 19%, mPFS 5.4 mo vs 4.2 mo (PBC)
Biomarker work ongoing to assess predictive role of HER3 IHC
Safety: Manageable, mainly hematologic and GI. ILD adjudicated in 5.2% (Grade 5 in 0.7%)
Early ILD onset (median ~4 wks), prompting close monitoring
OS: No improvement over chemo in 3rd interim analysis (HR 0.98)
Clinical takeaway: HER3-DXd offers a chemo-sparing option with intracranial activity and modest PFS gains, but without a confirmed OS benefit Will not be available to patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 00:35
Jun 3, 2025, 16:39